替吉奥联合奥沙利铂及多西紫杉醇治疗晚期胃癌的临床疗效和安全性评估

目的:观察替吉奥联合奥沙利铂及多西紫杉醇治疗晚期胃癌的近期疗效,并对其用药安全性进行评估。方法:选取2010年8月—2012年8月在我院接受治疗的晚期胃癌患者68例,随机分为对照组和观察组,每组34例。对照组患者采取5-FU+奥沙利铂+多西紫杉醇进行治疗,而观察组患者给予替吉奥+奥沙利铂+多西紫杉醇进行治疗,比较两组患者接受不同药物治疗所得到的近期疗效及不良反应的发生情况。结果:观察组治疗的总有效率为58.82%,而对照组治疗的总有效率为32.35%,观察组明显高于对照组,差异显著,具有统计学意义(P0.05);观察组患者治疗后的不良反应发生率为8.82%,而对照组患者治疗后的不良反应发生率为32.35%,观察组明显低于对照组,差异显著,具有统计学意义(P0.05)。结论:替吉奥联合奥沙利铂及多西紫杉醇治疗晚期胃癌疗效显著,不良反应少,患者耐受良好,值得进一步推广和应用。

Clinical Efficacy and Security Evaluation on Tegafur Combined with Oxaliplatin and Docetaxel for the Treatment of Advanced Gastric Cancer

Objective： To explore the clinical efficacy and security of tegafur combined with oxaliplatin and docetaxel on the treatment of advanced gastric cancer. Methods： 68 patients with advanced gastric cancer who were treated in our hospital from August 2010 to 2012 were selected and randomly divided into the observation group and the control group with 34 patients in each group. The patients in the control group were treated by 5-FU＋oxaliplatin＋docetaxel, while the patients in the observation group were treated by Gio＋oxaliplatin ＋docetaxel. Then the short-term efficacy and adverse reactions of patients were compared and analyzed between two groups. Results： The effective rate of the observation group was 58.82%, while the effective rate of the control group was 32.35%. The observation group was statistically significant higher than the control group （P〈0.05）. The incidence of adverse reactions in the observa- tion group was 8.82% which was lower than that of the control group 32.35%. There was statistically significant difference between two groups（P〈0.05）. Conclusion： It is suggested that the tegafur combined with oxaliplatin and docetaxel on the treatment of advanced gastric cancer should be well promoted in the clinical field with the advantages of obvious efficacy, less incidence of adverse reactions and easier adopted by patients.